Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsSolute carrier family 2, facilitated glucose transporter member 6 (SLC2A6), also known as Glucose transporter type 6 (GLUT-6) or Glucose transporter type 9 (GLUT-9), is a protein that in humans is encoded by the SLC2A6 gene. As a protein associated with the process of hexose transporting into mammalian cells, it contains 12 transmembrane domains and a number of critical conserved residues.
| Basic Information of SLC2A6 | |
| Protein Name | Solute carrier family 2, facilitated glucose transporter member 6 |
| Gene Name | SLC2A6 |
| Aliases | Glucose transporter type 6, GLUT-6, Glucose transporter type 9, GLUT-9 |
| Organism | Homo sapiens (Human) |
| UniProt ID | Q9UGQ3 |
| Transmembrane Times | 12 |
| Length (aa) | 507 |
| Sequence | MQEPLLGAEGPDYDTFPEKPPPSPGDRARVGTLQNKRVFLATFAAVLGNFSFGYALVYTSPVIPALERSLDPDLHLTKSQASWFGSVFTLGAAAGGLSAMILNDLLGRKLSIMFSAVPSAAGYALMAGAHGLWMLLLGRTLTGFAGGLTAACIPVYVSEIAPPGVRGALGATPQLMAVFGSLSLYALGLLLPWRWLAVAGEAPVLIMILLLSFMPNSPRFLLSRGRDEEALRALAWLRGTDVDVHWEFEQIQDNVRRQSSRVSWAEARAPHVCRPITVALLMRLLQQLTGITPILVYLQSIFDSTAVLLPPKDDAAIVGAVRLLSVLIAALTMDLAGRKVLLFVSAAIMFAANLTLGLYIHFGPRPLSPNSTAGLESESWGDLAQPLAAPAGYLTLVPLLATMLFIMGYAVGWGPITWLLMSEVLPLRARGVASGLCVLASWLTAFVLTKSFLPVVSTFGLQVPFFFFAAICLVSLVFTGCCVPETKGRSLEQIESFFRTGRRSFLR |
GLUT6 (SLC2A6) was first discovered in 2000 when searching the human genome for sequences similar to other members of the GLUT family. It contains an N-terminal dileucine motif, that is responsible for intracellular retention of the protein when overexpressed in primary rat adipocytes. Studies have shown that the expression of GLUT6 is predominantly detected in the brain, spleen, and leucocytes and is decreased with phenotypic switching from a proliferative to differentiated state in vascular smooth muscle cells. What’s more, alterations in GLUT6 expression have been linked to numerous cancers. It has been reported that GLUT6 is upregulated in multiple cancers tissues when compared to normal people, such as cutaneous melanoma, medullary breast carcinoma, oesophageal cancer, and head and neck squamous cell carcinoma.
Fig.1 Glucose Transporter in the Membrane.
This article aims to investigate how the loss of GLUT6 affects whole-body glucose homeostasis and metabolic physiology. It suggests that GLUT6 is not a major regulator of whole-body metabolic physiology; therefore, GLUT6 inhibition may have minimal adverse effects if targeted for cancer therapy.
This report proposes a hypothesis that the low extracellular Cl(-) affinity and apparent electroneutrality of oxalate efflux characterizing human SLC2A6 may partially explain the high human susceptibility to nephrolithiasis relative to that of the mouse. SLC26A6 sequence variant(s) are candidate risk modifiers for nephrolithiasis.
This article suggests that GLUT6 and GLUT8 appear to recycle in a dynamin-dependent manner between internal membranes and the plasma membrane in rat adipose cells, but are unresponsive to stimuli that induce translocation of GLUT4.
To provide high-quality products, we have developed an advanced Magic™ membrane protein production platform. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLC2A6 antibody development services.
With extensive experience and professional scientists, Creative Biolabs is dedicated to promoting global customers’ programs. Except for SLC2A6 membrane protein products, we also provide other membrane protein preparation services to meet every client’s specific requirements. To learn more information, please feel free to contact us for more information.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
